Phase I, Open-label, Single-center, Dose Escalation Study to Assess Safety and Tolerability of anti-CD19 CAR-T Cells in Patients with B-cell non-Hodgkin Lymphomas (CARMEN).

2024-519318-30-00 Protocol 2020/ABM/01/00107 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 25 Jun 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol 2020/ABM/01/00107

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 18
Countries 1
Sites 1

non-Hodgkin Lymphomas Subtypes: DLBCL - ORPHA: 544 Agressive B-cell non-Hodgkin lymphoma ORPHA: 300846 High grade B-cell lymphoma with MYCand/or BCL2 and/or BCL6 rearrangement ORPHA: 480541

Key facts

Sponsor
Wroclaw Medical University
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Hemic and Lymphatic Diseases [C15], Diseases [C] - Neoplasms [C04]
Trial duration
25 Jun 2025 → ongoing
Decision date (initial)
2025-03-27
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

non-Hodgkin Lymphomas Subtypes: DLBCL - ORPHA: 544 Agressive B-cell non-Hodgkin lymphoma ORPHA: 300846 High grade B-cell lymphoma with MYCand/or BCL2 and/or BCL6 rearrangement ORPHA: 480541

VersionLevelCodeTermSystem organ class
20.0 HLGT 10025320 Lymphomas non-Hodgkin's B-cell 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Wroclaw Medical University

Sponsor organisation
Wroclaw Medical University
Address
Ul. Wybrzeze Ludwika Pasteura 1
City
Wroclaw
Postcode
50-367
Country
Poland

Scientific contact point

Organisation
Wroclaw Medical University
Contact name
Information desk

Public contact point

Organisation
Wroclaw Medical University
Contact name
Information desk

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Poland Ongoing, recruiting 18 1
Rest of world 0

Investigational sites

Poland

1 site · Ongoing, recruiting
Wroclaw Medical University
Department and Clinic of Hematology, Cellular Therapies and Internal Medicine, Ul. Wybrzeze Ludwika Pasteura 1, 50-367, Wroclaw

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Poland 2025-06-25 2025-06-26

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-11-28 Poland Acceptable
2025-03-24
2025-03-27
2 SUBSTANTIAL MODIFICATION SM-1 2025-06-05 Poland Not acceptable
2025-09-08
2025-09-15
3 SUBSTANTIAL MODIFICATION SM-2 2026-01-29 Poland Acceptable
2026-03-07
2026-03-13